research 1726: Risk Decrease of Intra-Operative Bleeding During TURP with the Uptake of Finasteride: Evaluation of VEGF and CD34
Finasteride reduces bleeding risk during prostate surgery.
Search
for
Sort by
Research
420-450 / 1000+ results
research Comparison of Intra-operative Blood Loss in Patients Undergoing Mono-Polar TURP with and without Pre-operative 2 Weeks Use of Finasteride
Taking Finasteride before surgery reduces blood loss and surgery time.
research Estudo do estroma reativo prostático após a orquiectomia bilateral e posterior inibição da atividade da aromatase pela crisina e inibição da atividade da 5-alfa-redutase pela finasterida
research Analysis of benign prostatic obstruction surgery: A long-term evaluation in a real-life context
Prostate surgery is often effective long-term, but some patients may need more treatment or another surgery, especially if they had prostatitis before.
research Hormonal manipulation of benign prostatic hyperplasia
Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
research A new look at an old option in the treatment of early-stage prostate cancer: hormone therapy as an alternative to watchful waiting
Hormone therapy might be a proactive alternative to watchful waiting for early-stage prostate cancer, potentially improving survival without aggressive treatment downsides.
research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
research The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications
The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.
research The endoscopic surgical monitoring system-guided impact factors exploring of blood loss and fluid absorption during plasmakinetic TURP: a prospective study in high-risk BPH patients
Larger prostate size, longer surgery, and smoking increase risks, while finasteride and experienced surgeons reduce them during prostate surgery.
research MP09-16 5-ALPHA REDUCTASE INHIBITORS FOR MALE LOWER URINARY TRACT SYMPTOMS: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
research Should Finasteride Be Routinely Given Preoperatively for TURP?
Finasteride may reduce bleeding after TURP, but more research needed.
research Clinics in diagnostic imaging (221)
A bladder rupture from prostate treatment was healed with catheterization and antibiotics.
research Étude PCPT : les biais attendus et leur gestion
Systematic end-of-trial biopsies are the most reliable way to assess outcomes.
research Acute urinary retention: risks and management.
Older men with severe symptoms and larger prostates should focus on prevention, using finasteride and alpha-blockers to manage acute urinary retention.
research Three Considerations Before Advising 5-α-Reductase Inhibitors for Chemoprevention
5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.
research Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment
Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.
research 5-Alpha-Reductase Inhibitors and Combination Therapy
Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
research The effective course of finasteride pretreatment in decreasing blood loss associated with TURP
Taking finasteride for at least 3 months before TURP reduces blood loss.
research Patterns of Care for Newly Diagnosed Benign Prostatic Hyperplasia in the United States
Most care for benign prostatic hyperplasia follows guidelines, but 5-α reductase inhibitors are often used incorrectly.
research Medikamentöse Therapie des benignen Prostatasyndroms (BPS)
Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.
research 341 ANDROGENETIC ALOPECIA AT VARIOUS AGES AND PROSTATE CANCER RISK IN AN EQUAL ACCESS MULTIETHNIC CASE CONTROL SERIES OF VETERANS
Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.
research Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
research Editorial comment 1
Finasteride may reduce prostate cancer risk.
research Saw palmetto and finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome
research Slow progress in prostate cancer
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
research The research of Finasteride and Tamsulosin to reduce hemorrhage during TURP
Taking finasteride for over a month before surgery reduces blood loss during TURP.
research Benign Prostatic Hyperplasia and Sexual Dysfunction: Review of the Impact of New Medical and Surgical Therapies on Sexual Health
New BPH treatments have low sexual dysfunction risk but may not improve urinary symptoms as much as traditional surgery.
research Association of long-term 5α-reductase inhibitor use with survival in men with renal cell carcinoma: a nationwide population-based cohort study
Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
research Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content*
A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
research Referee report. For: Recent advances in treatment for Benign Prostatic Hyperplasia [version 1; referees: 2 approved]
BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.